(NASDAQ: IMMX) IMMIX Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 71.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 103.89%.
IMMIX Biopharma's earnings in 2025 is -$23,562,837.On average, 4 Wall Street analysts forecast IMMX's earnings for 2025 to be -$26,543,309, with the lowest IMMX earnings forecast at -$25,666,926, and the highest IMMX earnings forecast at -$27,147,710.
In 2026, IMMX is forecast to generate -$23,460,860 in earnings, with the lowest earnings forecast at -$23,692,547 and the highest earnings forecast at -$22,916,898.